Bristol Myers Squibb (BMY) delivered a mixed update for investors on [date not specified], raising its 2026 revenue forecast but lowering its profit outlook. The drugmaker now expects sales of $49.75 billion to $50.25 billion next year, up from its previous range of $49 billion to $50 billion. However, it cut its 2026 adjusted earnings forecast to $6.35 to $6.55 per share, down from $6.75 to $7.00, citing a 60-cent charge related to an acquisition.
The news came alongside a third-quarter report that beat Wall Street expectations on both the top and bottom lines. The company's newer medicines are increasingly driving growth, with that portfolio expanding 12% year-over-year. Key contributors include Breyanzi, a cell therapy for certain blood cancers, and Reblozyl, a treatment for anemia.
Why the outlook split?
Investors often see a company raise its sales guidance as a positive signal, but the simultaneous cut to earnings per share (EPS) can create confusion. The reason here is a one-time accounting charge tied to an acquisition. Such charges are common when companies buy other businesses and must account for costs like integration, restructuring, or amortization of intangible assets.
Adjusted earnings, also called non-GAAP earnings, exclude certain items that management believes don't reflect ongoing operations. By lowering its adjusted EPS guidance, Bristol Myers is signaling that the acquisition will have a tangible impact on near-term profitability, even though its core business is performing well.
For everyday investors, this highlights the importance of looking beyond headline numbers. A company can raise its sales outlook while cutting profit guidance, and both can be true simultaneously. The key is understanding what's driving each change.
Growth engine shifts to newer drugs
Bristol Myers has been navigating a challenging period as several of its older blockbuster drugs face patent expirations and increased competition from generics. In response, the company has invested heavily in newer therapies, including cell therapies and targeted treatments.
Breyanzi, a CAR-T cell therapy, has been a standout, with growing adoption in earlier lines of treatment. Reblozyl, developed with Celgene (now part of Bristol Myers), treats anemia in patients with certain blood disorders. Both drugs are part of a portfolio that grew 12% year-over-year, outpacing the company's overall growth.
This shift is typical for large pharmaceutical companies. When older drugs lose exclusivity, revenue can decline sharply unless new products fill the gap. Bristol Myers' ability to grow its newer portfolio is a positive sign, but the company still faces the challenge of offsetting declines in its legacy franchises.
What it means for investors
For investors, the revised guidance offers a clearer picture of what to expect from Bristol Myers in 2026. The higher sales range suggests confidence in the company's growth trajectory, while the lower EPS range reflects the cost of the acquisition.
It's also worth noting that the company's third-quarter beat indicates current momentum is strong. However, the acquisition charge is a reminder that deals can dilute near-term earnings, even if they're expected to create long-term value.
Investors should also consider the broader context. The pharmaceutical sector has seen a wave of M&A activity as companies seek to bolster their pipelines. Bristol Myers' acquisition is part of that trend, and its impact on earnings will be closely watched.
As always, it's important to evaluate any stock in the context of your own financial goals and risk tolerance. While Bristol Myers' newer drugs are promising, the company faces ongoing challenges, including patent cliffs and pricing pressures.
For more on how companies are navigating similar dynamics, see our coverage of Henkel's sales outlook and Prysmian's profit outlook.
